- The global market for HRT will increase from $14.7 billion in 2007 to an estimated $15.8 billion by the end of 2008. It should reach $25.9 billion in 2013, a compound annual growth rate (CAGR) of 10.4%.
- Antiestrogens, SERMs, antiandrogens, aromatase inhibitors and LH RH agonists have the largest share of the market, worth $7.5 billion in 2007. This is expected to increase to $8.3 billion in 2008 and $13.7 billion in 2013, for a CAGR of 10.7%.
- Recombinant growth, thyroid and testosterone hormone therapies have the second largest market share, generating $4.1 billion in 2007 and an estimated $4.4 billion in 2008. This should increase at a CAGR of 9.9% to reach $7.0 billion in 2013.
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study is to provide an overview of the current and potential global market for hormone replacement therapy and other hormone therapies. The report determines the market size, market leaders, and factors affecting the market of hormone therapies.
The overview of types of diseases and different hormone therapies is also examined along with sale figures over the five-year period from 2008 to 2013. Companies that manufacture and sell hormonal drugs to treat various types of diseases are profiled, and the factors affecting markets for these products and how those markets are likely to change are analyzed. Revenues have been broken down by type of therapy and by region.
The key objective of this report is to present a comprehensive analysis of the current market and the future direction of hormone replacement and other hormonal therapies with an emphasis on new developments.
REASONS FOR DOING THIS STUDY
Due to continuous increase in research and development in the field of hormones and the requirement for safer and more effective pharmaceutical drugs/therapies, companies are investing in clinical trials to develop these products, and to lessen side effects.
This study looks at almost all types of therapies/products used in hormone therapies, excluding the parathyroids. It examines the research and development of new products as well as ongoing clinical trials. Changes in R&D or in clinical trial results can have a marked effect on the global market; therefore, it is important to research the hormone therapy sector. Additionally, there is a section covering the use of these drug therapies by disease sector.
This study contributes to the areas of market growth and decline in hormonal therapies from the point of view of the manufacturer. Therefore, it will be of interest to the pharmaceutical and biopharmaceutical industries, as well as clinics and hospitals.
SCOPE OF REPORT
The scope of this study encompasses global markets for hormonal therapies. BCC analyzes each market and its market leaders; different types of therapies; the regulatory environment; the different disease sectors for the use of hormonal therapies; and market projections and market share. Technological issues include the latest trends and new developments.
A comprehensive literature search was conducted. The literature included technical newsletters and journals as well as many other sources. Data were collected through interviews and correspondence with various pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.
BCC surveyed many companies to obtain data for this study. Included were manufacturers and the end users of the cancer drugs. We gathered the data from the industries; spoke with officials of this industry; and consulted newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial and trade information and government sources.
Shalini Shahani Dewan holds a masters degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shahani was awarded a gold medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC include Reagents of Chromatography; Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs, Implants and Devices; Imaging Reagents; Contract Manufacturing, Research and Packaging; The Dynamic Media, Sera and Reagent market in Biotechnology; Opportunities in Chiral Technology; Behavioral and Emotional Disorders in Children and Adolescents; and Pharmaceutical Regulatory Industry, and many more.